Alain Algazi
University of California, San Francisco
H-index: 52
North America-United States
Top articles of Alain Algazi
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
The neutrophil‐to‐lymphocyte ratio in salivary gland cancers treated with pembrolizumab | Head & Neck | Rex H Lee Angeline Truong Xin Wu Hyunseok Kang Alain P Algazi | 2024/1 |
Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma | Journal of Clinical Oncology | Christopher A Barker Suzanne Dufault Sarah T Arron Alan L Ho Alain P Algazi | 2024/4 |
Treatment Modality Impact on Patient‐Reported Quality of Life in Human Papilloma Virus‐Associated Oropharyngeal Carcinoma | The Laryngoscope | Karolina A Plonowska‐Hirschfeld Arushi Gulati Erika M Stephens Edgar Ochoa Mary Jue Xu | 2023/9/28 |
N17350 kills cancer cells, spares immune cells, and regresses CDX tumors from chemotherapy naive and experienced patients | Cancer Research | Chang Cui Ravindra Gujar Christine Lee Maria Fumagalli Nicole Martinez | 2024/3/22 |
Carboplatin and paclitaxel after anti‐PD‐1 or anti‐PD‐L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck | Head & Neck | Audrey Humphries Connie J Zhou Madeleine Welsh Melinda Lem Hyunseok Kang | 2024/2 |
A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers | Cancer | Alain P Algazi James Moon Christopher D Lao Bartosz Chmielowski Kari L Kendra | 2024/1/23 |
Safety and efficacy of SNS-301 plus pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). | Alain Patrick Algazi William Smith Justine Yang Bruce Dong Moon Shin Ann Wild Gramza | 2023/6/1 | |
Safety and efficacy of MEDI0457 plus durvalumab in patients with human papillomavirus–associated recurrent/metastatic head and neck squamous cell carcinoma | Clinical Cancer Research | Charu Aggarwal Nabil F Saba Alain Algazi Ammar Sukari Tanguy Y Seiwert | 2023/2/1 |
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 keynote‐158 study | Cancer | Do‐Youn Oh Alain Algazi Jaume Capdevila Federico Longo Wilson Miller Jr | 2023/4/15 |
676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R … | Terrence Fisher Elizabeth Evans Crystal Mallow Amber Foster John Leonard | 2023/11/1 | |
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes | Cell | Maha K Rahim Trine Line H Okholm Kyle B Jones Elizabeth E McCarthy Candace C Liu | 2023/3/16 |
782 TransCon TLR7/8 agonist induces sustained local and systemic immune activation in patients with solid tumors | Diwakar Davar Mette Kriegbaum Morteza Aghmesheh Alain Algazi David Bajor | 2023/11/1 | |
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors | Cancer | Aung Naing Alain P Algazi Gerald S Falchook Benjamin C Creelan John Powderly | 2023/1/1 |
1135P Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus … | Annals of Oncology | R Huang G Youssef T Nelson P Wen P Forsyth | 2023/10/1 |
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial | Annals of Oncology | ATC Chan VHF Lee R-L Hong M-J Ahn WQ Chong | 2023/3/1 |
A prospective evaluation of neck and shoulder function following treatments of early‐stage human papillomavirus‐associated oropharynx cancer | Clinical Otolaryngology | Arushi Gulati Karolina Plonowska‐Hirschfeld Erika M Stephens Sagar Kansara Aaron L Zebolsky | 2023/9 |
Melanoma risk during immunomodulating treatment | Yixuan James Zheng Wilson Ho Martina Sanlorenzo Igor Vujic Adil Daud | 2022/12/1 | |
Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment-naïve head and neck squamous cell carcinoma: results from a multicenter, phase II trial | Clinical cancer research | Ezra EW Cohen Lisle Nabell Deborah J Wong Terry Day Gregory A Daniels | 2022/3/15 |
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity | Molecular Therapy-Oncolytics | Jack Y Lee Bianca Nguyen Anandaroop Mukhopadhyay Mia Han Jun Zhang | 2022/6/16 |
Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: phase 2 proof-of-concept study | Clinical Cancer Research | Matthew H Taylor Courtney B Betts Lauren Maloney Eric Nadler Alain Algazi | 2022/3/1 |
